Pharmaceutical Industry in Egypt
eSectoral Survey
Pharmaceutical Industry in Egypt
November 2010
Sectoral survey: Pharmaceutical Industry
Index Page
1. Introduction 2. Definition 3. Regulatory framework
3.1.Regulatory body 3.2.Pricing
3.3.TRIPS
3 4 4
4. Market analysis
4.1.Market structure 4.2.Consumption 4.3.Production 4.4.Key players
7
5. Trade
5.1.Exports 5.2.Imports 5.3.Balance of trade
9
6. SWOT analysis 7. Outlook 8. Recommendations 9. Conclusion Appendix References
11 12 13 13
2
Sectoral survey: Pharmaceutical Industry
1- Introduction
Producing medicine is a strategic industry due to its importance on the social level and significant role in protecting the human health. Billions of dollars are annually invested in research and development around the world to support this industry aiming to increase human 's ability to face different kinds of diseases which is obviously reflected in the rising life expectancy for people especially in industrial countries where medicine production is highly concentrated in those countries .This industry has started in Egypt with Tal 'at Harb and the establishment of the first Egyptian pharmaceutical company in 1939 under the name of "Misr Company for Pharmaceuticals" believing in the strategic importance of a strong national pharmaceutical industry. It has undergone many changes along the history witnessing a wide variation in the key players controlling the market, attracting many investments to that growing field that forms about 30% of the pharmaceuticals supply in the MENA market, according to the American Chamber of Commerce in Egypt. So, this paper is spotting the main features of the pharmaceutical sector including demand, supply, patterns of trade and regulatory framework that organizes the sector. The paper also tackles strengths of the sector and particularly after liberalizing the industry, introducing an efficient registration system for new medicines and other factors that have collectively helped
Pharmaceutical Industry in Egypt
November 2010
Sectoral survey: Pharmaceutical Industry
Index Page
1. Introduction 2. Definition 3. Regulatory framework
3.1.Regulatory body 3.2.Pricing
3.3.TRIPS
3 4 4
4. Market analysis
4.1.Market structure 4.2.Consumption 4.3.Production 4.4.Key players
7
5. Trade
5.1.Exports 5.2.Imports 5.3.Balance of trade
9
6. SWOT analysis 7. Outlook 8. Recommendations 9. Conclusion Appendix References
11 12 13 13
2
Sectoral survey: Pharmaceutical Industry
1- Introduction
Producing medicine is a strategic industry due to its importance on the social level and significant role in protecting the human health. Billions of dollars are annually invested in research and development around the world to support this industry aiming to increase human 's ability to face different kinds of diseases which is obviously reflected in the rising life expectancy for people especially in industrial countries where medicine production is highly concentrated in those countries .This industry has started in Egypt with Tal 'at Harb and the establishment of the first Egyptian pharmaceutical company in 1939 under the name of "Misr Company for Pharmaceuticals" believing in the strategic importance of a strong national pharmaceutical industry. It has undergone many changes along the history witnessing a wide variation in the key players controlling the market, attracting many investments to that growing field that forms about 30% of the pharmaceuticals supply in the MENA market, according to the American Chamber of Commerce in Egypt. So, this paper is spotting the main features of the pharmaceutical sector including demand, supply, patterns of trade and regulatory framework that organizes the sector. The paper also tackles strengths of the sector and particularly after liberalizing the industry, introducing an efficient registration system for new medicines and other factors that have collectively helped
References: "Industry Forecast Senario." www.businessmonitor.com . Business Monitor International, 14 Nov. 2009. Web. 15 Sep 2010. . "WPM Q2 2010." www.marketresearch.com . Espicom Healthcare Intelligence, Q2 2010. Web. 15 Sep 2010. . "Biological and Biosimilar Medicines." www.europabio.org . Europabio, n.d. Web. 15 Sep 2010. . " P h i l o s o p h y: T R I P S a t t e m p t s t o s t r i k e a b a l a n c e . " w w w . w t o . o r g . W o r l d T r a d e Organization, n.d. Web. 15 Sep 2010. . " E g yp t - I n c r e a s i n g i n v e s t m e n t i n p h a r m a c e u t i c a l s e c t o r . " www.english.globalarabnetwork. Global Arab Network, 15 Feb. 2010. Web. 15 Sep 2010. . "Progress in Essential Drugs and Medicines Policy 1998 -1999." www.apps.who.int . World Health Organization, n.d. Web. 16 Sep 2010. . "Trade Performance HS." www.intracen.org . International Trade Center, 2008. Web. 21 Sep 2010. . " T h e E g yp t i a n P h a r m a c e u t i c a l I n d u s t r y . " w w w . u b i c consulting.com. UBIC Consulting, n.d. Web. 31 Oct 2010. . " R e c e n t l y r e l e a s e d m a r k e t s t u d y: E g yp t P h a r m a c e u t i c a l s & H e a l t h c a r e R e p o r t Q 3 2010." www.pr-inside.com. PR-inside, n.d. Web. 31 Oct 2010. . 16 Sectoral survey: Pharmaceutical Industry "The Middle East: Pharma’s New Frontier." www.contractpharma.com. PRinside, n.d. Web. 31 Oct 2010. . " E g yp t p h a r m a a n d b i o t e c h : S u b - s e c t o r u p d a t e . " w w w . e i u . c o m . E c o n o m i s t Intelligence Unit, Jan 21 2010 . Web. 31 Oct 2010. " I n v e s t i n E g yp t . " w w w . d o c s t o c . c o m . M i n i s t r y o f I n v e s t m e n t , 2 0 0 8 . W e b . 3 1 O c t 2010. . www.holdipharma.com.eg www.eipico.com.eg www.amoun.com www.intracen.org www.espicom.com Disclaimer The information contained in this publication is based on sources that AlexBank believes to be reliable and accurate. But the bank does not make any guarantee to the accuracy or reliability of such information. All opinions and estimates included in this report are subject to change without prior notice . Nothing herein constitutes an offer, solicitation to the purchase or sale of any products, services or conducting any investments. AlexBank shall not be liable for any losses or damages incurred or suffered as a result of using its publications and in using the Website 's contents and functions. The data and/or information in the publications are not considered official document in any disputes or conflicts reviewed by security or regulatory authorities. The Bank keeps all the literary and moral rights on its information and analysis and no part of this publication or excerpt of its content may be redistributed, reproduced or conveyed in any form, written or oral, to any third party without a prior written consent of AlexBank and also referring to the source. 17